Compare HERE & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | OKYO |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.1M | 87.6M |
| IPO Year | 2022 | 2021 |
| Metric | HERE | OKYO |
|---|---|---|
| Price | $1.90 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 17.0K | ★ 59.0K |
| Earning Date | 06-05-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.29 | N/A |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.34 |
| 52 Week High | $5.80 | $3.20 |
| Indicator | HERE | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 43.89 |
| Support Level | $1.81 | $1.46 |
| Resistance Level | $1.95 | $1.72 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 89.03 | 29.09 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.